Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

Cunningham, D, Stenning, SP, Smyth, EC et al. (15 more authors) (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncology, 18 (3). pp. 357-370. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Cunningham, D
  • Stenning, SP
  • Smyth, EC
  • Okines, AF
  • Allum, WH
  • Rowley, S
  • Stevenson, L
  • Grabsch, HI ORCID logo https://orcid.org/0000-0001-9520-6228
  • Alderson, D
  • Crosby, T
  • Griffin, SM
  • Mansoor, W
  • Coxon, FY
  • Falk, SJ
  • Darby, S
  • Sumpter, KA
  • Blazeby, JM
  • Langley, RE
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Dates:
  • Accepted: 31 October 2016
  • Published (online): 3 February 2017
  • Published: March 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 31 Jan 2017 12:48
Last Modified: 28 Jan 2020 17:27
Published Version: https://doi.org/10.1016/S1470-2045(17)30043-8
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S1470-2045(17)30043-8

Share / Export

Statistics